Literature DB >> 17090612

Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart.

Mattie Lenzen1, Lars Ryden, John Ohrvik, Malgorzata Bartnik, Klas Malmberg, Wilma Scholte Op Reimer, Maarten L Simoons.   

Abstract

AIMS: Although diabetes is known to be a major contributor to cardiovascular diseases, as well as an independent predictor for adverse outcomes in patients with coronary artery disease (CAD), information on the prognosis of patients with CAD and newly diagnosed diabetes or impaired glucose regulation (IGR) is scarce. The objective of this study was to explore 1-year outcome in relation to different glucometabolic states of patients participating in the Euro Heart Survey on diabetes and the heart. METHODS AND
RESULTS: In 4676 out of 4961 patients, information on the relation between 1-year outcome and glucometabolic state, which was based on oral glucose tolerance test (OGTT) or fasting glucose plasma, was available. A normal glucose metabolism was identified in 947 patients, IGR (impaired fasting glucose or impaired glucose tolerance) in 1116 patients, and diabetes in 1877 patients of whom 1425 were previously diagnosed and 452 newly diagnosed. In total, 736 patients could not be classified, as no OGTT or fasting plasma glucose was performed. Previously recognized and newly detected diabetes was associated with an increased risk of 1-year mortality when compared with patients with normal glucose regulation [hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.5-3.8 and HR 2.0, 95% CI 1.1-3.6, respectively)]. IGR, however, could not be identified as an independent predictor for 1-year mortality (HR 1.1, 95% CI 0.6-1.9).
CONCLUSION: This study confirmed that patients with CAD and known diabetes are at high risk for mortality and cardiovascular events and demonstrated that patients with newly diagnosed diabetes are at intermediate risk for adverse outcomes. IGR, however, could not be identified as an independent predictor for adverse outcomes during the 1-year follow-up period.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090612     DOI: 10.1093/eurheartj/ehl363

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  35 in total

1.  Implementation of Cardiovascular Disease Prevention Guidelines in Clinical Practice-Can We Do Better?

Authors:  Kornelia Kotseva
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-12

2.  [Prevalence of undetected diabetes mellitus in invasive and interventional cardiology. Silent diabetes in the catheterization laboratory].

Authors:  R Dörr; J Stumpf; S G Spitzer; B Krosse; D Tschöpe; T Lohmann; O Schnell
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

3.  First experience with sodium-glucose co-transporter 2 inhibitors in Polish patients with cardiovascular diseases.

Authors:  Ewa Dziewięcka; Mateusz Winiarczyk; Matylda Gliniak; Monika Kaciczak; Sylwia Wiśniowska-Śmiałek; Aleksandra Karabinowska; Katarzyna Holcman; Magdalena Kostkiewicz; Marta Hlawaty; Agata Leśniak-Sobelga; Piotr Podolec; Paweł Rubiś
Journal:  Cardiol J       Date:  2020-08-13       Impact factor: 2.737

4.  Detection of glucose abnormalities in patients with acute coronary heart disease: study of reliable tools in clinical practice.

Authors:  M I Del Olmo; J F Merino-Torres; M Argente; A Ramos; M S Navas; V Campos; R Cámara; A Pérez-Lázaro
Journal:  J Endocrinol Invest       Date:  2011-05-30       Impact factor: 4.256

5.  A prospective study of fasting plasma glucose and risk of stroke in asymptomatic men.

Authors:  Xuemei Sui; Carl J Lavie; Steven P Hooker; Duck-Chul Lee; Natalie Colabianchi; Chong-Do Lee; Steven N Blair
Journal:  Mayo Clin Proc       Date:  2011-09-12       Impact factor: 7.616

Review 6.  Overview of the importance of glycaemic control for cardiovascular events in the in-and out-patient setting.

Authors:  Matteo Anselmino; Klas Malmberg; Linda Mellbin; Lars Rydén
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

7.  Could pre-diabetes be considered a clinical condition? opinions from an endocrinologist and a cardiologist.

Authors:  Maria Eliane C Magalhães; Breno A Cavalcanti; Saulo Cavalcanti
Journal:  Diabetol Metab Syndr       Date:  2010-01-15       Impact factor: 3.320

8.  The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively.

Authors:  Michal Mazurek; Jacek Kowalczyk; Radoslaw Lenarczyk; Teresa Zielinska; Agnieszka Sedkowska; Patrycja Pruszkowska-Skrzep; Andrzej Swiatkowski; Beata Sredniawa; Oskar Kowalski; Lech Polonski; Krzysztof Strojek; Zbigniew Kalarus
Journal:  Cardiovasc Diabetol       Date:  2012-06-28       Impact factor: 9.951

Review 9.  Approaches to prevention of cardiovascular complications and events in diabetes mellitus.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Metabolic syndrome, dysglycaemia and vascular disease: making sense of the evidence.

Authors:  David Preiss; Naveed Sattar
Journal:  Heart       Date:  2007-12       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.